Kshirsagar Rijul S, Eide Jacob G, Prasad Aman, Carey Ryan M, Rajasekaran Karthik, Brant Jason A, Newman Jason G, Palmer James N, Adappa Nithin D
Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, United States.
J Neurol Surg B Skull Base. 2022 Jun 6;84(3):232-239. doi: 10.1055/a-1780-4157. eCollection 2023 Jun.
Although adjuvant radiotherapy may be indicated in patients with sinonasal squamous cell carcinoma (SNSCC) following primary surgery, some patients choose to forgo recommended postoperative radiation therapy (PORT). This study aimed to elucidate factors associated with patient refusal of recommended PORT in SNSCC and examine overall survival. Retrospective analysis of patients with SNSCC treated with primary surgery from the National Cancer Database diagnosed between 2004 and 2016. A multivariable logistic regression model was created to determine the association between clinical or demographic covariates and likelihood of PORT refusal. Unadjusted Kaplan-Meier estimates, log-rank tests, and a multivariable Cox proportional hazard model were used to assess overall survival. A total of 2,231 patients were included in the final analysis, of which 1,456 (65.3%) were males and 73 (3.3%) refused recommended PORT. Patients older than 74 years old were more likely to refuse PORT than those younger than 54 (odds ratio [OR] 3.43, 95% confidence interval [CI]: 1.84-6.62). Median survival among the entire cohort, those who received recommended PORT, and those who refused PORT was 83.0 months (95% CI: 74.6-97.1), 83.0 months (95% CI: 74.9-98.2), and 63.6 months (95% CI: 37.3-101.4), respectively. Refusal of PORT was not associated with overall survival (hazard ratio: 0.99, 95% CI: 0.69-1.42). PORT refusal in patients with SNSCC is rare and was found to be associated with several patient factors. The decision to forgo PORT is not independently associated with overall survival in this cohort. Further study is required to determine the clinical implications of these findings as the treatment decisions are complex.
尽管辅助放疗可能适用于鼻窦鳞状细胞癌(SNSCC)患者在初次手术后的情况,但一些患者选择放弃推荐的术后放疗(PORT)。本研究旨在阐明SNSCC患者拒绝推荐PORT的相关因素并检查总生存期。
对2004年至2016年间从国家癌症数据库中确诊的接受初次手术治疗的SNSCC患者进行回顾性分析。创建多变量逻辑回归模型以确定临床或人口统计学协变量与PORT拒绝可能性之间的关联。使用未调整的Kaplan-Meier估计、对数秩检验和多变量Cox比例风险模型来评估总生存期。
最终分析共纳入2231例患者,其中1456例(65.3%)为男性,73例(3.3%)拒绝推荐的PORT。74岁以上的患者比54岁以下的患者更有可能拒绝PORT(比值比[OR]3.43,95%置信区间[CI]:1.84-6.62)。整个队列、接受推荐PORT的患者以及拒绝PORT的患者的中位生存期分别为83.0个月(95%CI:74.6-97.1)、83.0个月(95%CI:74.9-98.2)和63.6个月(95%CI:37.3-101.4)。拒绝PORT与总生存期无关(风险比:0.99,95%CI:0.69-1.42)。
SNSCC患者拒绝PORT的情况很少见,且发现与几个患者因素有关。在这个队列中,放弃PORT的决定与总生存期没有独立关联。由于治疗决策复杂,需要进一步研究以确定这些发现的临床意义。